Ireland
--:--IST
Recruiting Observational

Maternal Grandmothers in the Born in Guangzhou Cohort Study

NCT03633162 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2018-05-21
Last updated
2026-09-16

Condition(s) studied

Hereditary TransmissionImmune DevelopmentChildhood ObesityHost and MicrobiomeNeurodevelopment

Study summary

The MGBIG is a study exploring cross-generational effects in 5000 women and their children and grandchildren located in Guangzhou, China. Its initial aim is to facilitate research on understanding the interplay between genes and environmental factors on disease etiology and on explaining the cause of the disease from the perspective of "grandmother-mother-child" heredity. Data are collected regarding environmental exposures, lifestyle, and social support on grandmother from birth to old age. Biological samples including blood and tissue samples are collected.

Eligibility

Sex
FEMALE
Min age
36 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Maternal Grandmother' grandchildren delivered in Guangzhou Women and Children's Medical Center 2. Baseline information of maternal grandmother's daughter during pregnancy available Exclusion Criteria: 1. Significant cardiovascular abnormalities 2. Intelligent obstacle, intellectual disabilities or gawkish condition

Primary outcome measure(s)

  • Haplotypes transfered by non-inherited maternal antigens from maternal grandmother to female offspring — From the date of her daughter get pregnant until the date her grandchild/grandchildren is/are given birth
    Assessed by analyses of MHC haplotypes, HLA haplotypes, and levels of non-inherited maternal antigens of mother and offspring, and pregnancy complication of maternal grandmothers and mothers

Trial sites (1)

FacilityCityRegionStatus
Guangzhou Women and Children's Medical Center Guangzhou Guangdong Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03633162 on ClinicalTrials.gov ↗ ← All trials in China